Heroin intoxication in a dog

[en] An 11-month-old intact male boxer cross was presented unconscious following oral heroin consumption. At home, intramuscular naloxone given by the owner showed no obvious improvements. Intravenous naloxone given in the hospital quickly reversed the clinical signs. The owners were not able to afford hospitalisation and the animal was discharged against medical advice. No signs of rebound opioid toxicity were reported. This case report describes the clinical presentation and treatment of a case of heroin intoxication in a dog.

Disciplines :

Veterinary medicine & animal health

Author, co-author :

McDermott, Fergal ; ULiège

Henriksson, Andrea E.; University of Saskatchewan

Wismer, Tina A.; ASPCA Animal Poison Control Center

Language :

English

Title :

Heroin intoxication in a dog

Publication date :

2021

Journal title :

Veterinary Record Case Reports

eISSN :

2052-6121

Publisher :

BMJ Publishing Group, London, United Kingdom

Volume :

Issue :

Pages :

e83

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 January 2022

Statistics

Number of views

70 (2 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

United Nations Office on Drugs and Crime. World drug report 2020. 2020. https://wdr.unodc.org/wdr2020/index.html
Williams RH, Erickson T. Emergency diagnosis of opioid intoxication. Lab Med 2000;31(6):334–42.
Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Population pharmacokinetics of heroin and its major metabolites. Clin Pharmacokinet. 2006;45(4):401–17.
Garrett ER, Gürkan T. Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. J Pharm Sci. 1980;69(10):1116–34.
Skoppl G, Ganssmann B, Cone EJ, Aderjan R. Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. J Anal Toxicol. 1997;21(2):105–11.
Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 1983;33:773–6.
NIDA. Heroin DrugFacts. National Institute on Drug Abuse, 24 Jul. 2020, https://www.drugabuse.gov/publications/drugfacts/heroin Accessed 14 Aug 2020.
Brashear RE, Cornog JL, Forney RB. Cardiovascular effects of heroin in the dog. J Lab Clin Med. 1971;78(5):794–5.
Bailey JE, Campagna E, Dart RC, RADARS System Poison Center Investigators. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med. 2009;53(4):419–24.
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.
Meola SD, Tearney CC, Haas SA, Hackett TB, Mazzaferro EM. Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005–2010). J Vet Emerg Crit Care. 2012;22(6):690-6.
Howard-Azzeh M, Pearl DL, O'Sullivan TL, Berke O. The identification of risk factors contributing to accidental opioid poisonings in companion dogs using data from a North American poison control center (2006-2014). PLoS One. 2020;15(1):e0227701.
Palmer LE, Gautier A. Clinical update: the risk of opioid toxicity and naloxone use in operational K9s. J Spec Oper Med. 2017;17(4):86–92.
Volmer PA. “Recreational” drugs. In Small animal toxicology. Philadelphia: WB Saunders; 2013. p. 309–34.
Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema: a case series. Chest. 2001;120(5):1628–32.
Baumann A, Audibert G, McDonnell J, Mertes PM. Neurogenic pulmonary edema. Acta Anaesthesiol Scand. 2007;51(4):447–55.
Lewenstein MJ, Fishman J. Morphine derivative. US Patent. 1966;3.
Foldes FF, Duncalf D, Kuwabara S. The respiratory, circulatory, and narcotic antagonistic effects of nalorphine, levallorphan, and naloxone in anaesthetized subjects. Can Anaesth Soc J. 1969;16(2):151–61.
Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1(3):219–30.
Essler, JL., et al. A randomized cross-over trial comparing the effect of intramuscular versus intranasal naloxone reversal of intravenous fentanyl on odor detection in working dogs. Animals. 2019;9(6):385.
Wahler BM, Lerche P, Ricco Pereira CH, Bednarski RM, KuKanich B, Lakritz J, Aarnes TK. Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. Am J Vet Res. 2019;80(7):696–701.
Tonozzi C, McMichael M, Mitek A, Weir W, Smith M, Cornwell N. Non-veterinary emergency care of law enforcement canines at mass gathering events a pilot training course for collegiate-based EMS providers. J Coll Emerg Med Serv. 2019;2(1):03.
Johnson RM, Azimi N, Schnipper EF. Pharmacokinetics of transbuccal swab-administered naloxone-HCl using a novel plant-based resin formulation in dogs. bioRxiv. 2020 Jan 1.
Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243–53.
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63–8.
Copland VS, Haskins SC, Patz J. Naloxone reversal of oxymorphone effects in dogs. Am J Vet Res. 1989;50(11):1854.
Mills CA, Flacke JW, Miller JD, Davis LJ, Bloor BC, Flacke WE. Cardiovascular effects of fentanyl reversal by naloxone at varying arterial carbon dioxide tensions in dogs. Anesth Analg. 1988;67(8):730–6.
Patschke D, Eberlein HJ, Hess W, Tarnow J, Zimmermann G. Antagonism of morphine with naloxone in dogs: cardiovascular effects with special reference to coronary circulation. Br J Anaesth. 1977;49(6):525–33.
Hovda L, Brutlag A, Poppenga RH, Peterson K, editors. Opiates and opioids. In Blackwell's five-minute veterinary consult clinical companion: small animal toxicology. Iowa, US: John Wiley & Sons; 2016, p. 292.
Dyson DH, Doherty T, Anderson GI, McDonell WN. Reversal of oxymorphone sedation by naloxone, nalmefene, and butorphanol. Vet Surg. 1990;19(5):398–03.
Silverstein D, Hopper K. Small animal critical care medicine-E-Book. Elsevier Health Sciences, St. Louis, Missouri; 2014, p. 162.
Watson WA, Steele MT, Muelleman RL, Rush MD. Opioid toxicity recurrence after an initial response to naloxone. J Toxicol Clin Toxicol. 1998;36(1-2):11–7.
Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med. 2003;10(8):893–6.
Greene JA, Deveau BJ, Dol JS, Butler MB. Incidence of mortality due to rebound toxicity after ‘treat and release’ practices in prehospital opioid overdose care: a systematic review. Emerg Med J. 2019;36(4):219–24.
Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone?. Clin Toxicol. 2017;55(2):81–7.
Juurlink DN. Activated charcoal for acute overdose: a reappraisal. Br J Clin Pharmacol. 2016;81(3):482–7.
Darke S. Heroin overdose. Addiction. 2016;111(11):2060–3.
Boyer E, Shannon M. Which drug tests in medical emergencies?. Clin Chem. 2003;49(3):353–4.